Maurine Mumo Mutua, Cyrus Kathiiko, Mary N Wachira, Betty Muriithi, James Nyangao, Samoel A Khamadi, Satoshi Komoto, Kouichi Morita, Yoshio Ichinose, Ernest A Wandera
{"title":"Epidemiological trends of diarrheal viruses in central and western Kenya before and after Rotavirus vaccine introduction.","authors":"Maurine Mumo Mutua, Cyrus Kathiiko, Mary N Wachira, Betty Muriithi, James Nyangao, Samoel A Khamadi, Satoshi Komoto, Kouichi Morita, Yoshio Ichinose, Ernest A Wandera","doi":"10.1186/s41182-025-00716-6","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Rotavirus, norovirus, adenovirus (type 40/41) and astrovirus are the most significant viral etiological agents of acute gastroenteritis in young children globally. Kenya introduced the rotavirus vaccine into her National Immunization Program in July 2014, which has led to a significant decline in the prevalence of rotavirus. We sought to assess the impact of rotavirus vaccination on the epidemiological trends of other diarrhea-associated enteric viruses across different regions in Kenya.</p><p><strong>Methodology: </strong>Using conventional and multiplex RT-PCR, we analyzed a total of 716 fecal samples for adenovirus, astrovirus and norovirus from children aged below 5 years presenting with acute gastroenteritis but tested negative for rotavirus at Mbita Sub-County Referral Hospital in Western Kenya and Kiambu County Referral Hospital in Central Kenya before (2011-2013) and after (2019-2020) rotavirus vaccine introduction.</p><p><strong>Results: </strong>Following the rotavirus vaccine introduction, there was no significant difference in norovirus and astrovirus prevalence post-vaccine introduction in both Central (norovirus- 5.4% vs 5.9%; astrovirus- 2% vs 2.4%) and Western Kenya (norovirus- 2% vs 3%; astrovirus 3.3% vs 5.9%). Although the prevalence of adenovirus increased substantially in Western Kenya (9% vs 12.4%), there was a significant decrease in adenovirus in Central Kenya (17%, vs 6%, p = 0.007). Before the introduction of the rotavirus vaccine, a large proportion of adenovirus cases occurred at 6-8 months in Central Kenya and 12-23 months in Western Kenya, while norovirus prevalence was highest at 12-23 months in Central and 3-5 months in Western Kenya. Astrovirus infections in Central Kenya were predominantly among children aged 12-23 months, both before and after the vaccine. Following vaccine introduction, a large proportion of adenovirus cases occurred among children aged 12-23 months in both regions. Norovirus peaked at 12-23 months in Central Kenya and showed dual peaks at 3-5 and 9-11 months in Western Kenya. Astrovirus infections in Western Kenya shifted from peaks at 6-8 and 24-59 months pre-vaccine to 9-11 months post-vaccine.</p><p><strong>Conclusion: </strong>Our data demonstrate the burden and changing epidemiology of enteric viruses in Western and Central Kenya and underscores the need for continued monitoring to guide the design and implementation of appropriate public health interventions.</p>","PeriodicalId":23311,"journal":{"name":"Tropical Medicine and Health","volume":"53 1","pages":"60"},"PeriodicalIF":3.6000,"publicationDate":"2025-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12034208/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tropical Medicine and Health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s41182-025-00716-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"TROPICAL MEDICINE","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Rotavirus, norovirus, adenovirus (type 40/41) and astrovirus are the most significant viral etiological agents of acute gastroenteritis in young children globally. Kenya introduced the rotavirus vaccine into her National Immunization Program in July 2014, which has led to a significant decline in the prevalence of rotavirus. We sought to assess the impact of rotavirus vaccination on the epidemiological trends of other diarrhea-associated enteric viruses across different regions in Kenya.
Methodology: Using conventional and multiplex RT-PCR, we analyzed a total of 716 fecal samples for adenovirus, astrovirus and norovirus from children aged below 5 years presenting with acute gastroenteritis but tested negative for rotavirus at Mbita Sub-County Referral Hospital in Western Kenya and Kiambu County Referral Hospital in Central Kenya before (2011-2013) and after (2019-2020) rotavirus vaccine introduction.
Results: Following the rotavirus vaccine introduction, there was no significant difference in norovirus and astrovirus prevalence post-vaccine introduction in both Central (norovirus- 5.4% vs 5.9%; astrovirus- 2% vs 2.4%) and Western Kenya (norovirus- 2% vs 3%; astrovirus 3.3% vs 5.9%). Although the prevalence of adenovirus increased substantially in Western Kenya (9% vs 12.4%), there was a significant decrease in adenovirus in Central Kenya (17%, vs 6%, p = 0.007). Before the introduction of the rotavirus vaccine, a large proportion of adenovirus cases occurred at 6-8 months in Central Kenya and 12-23 months in Western Kenya, while norovirus prevalence was highest at 12-23 months in Central and 3-5 months in Western Kenya. Astrovirus infections in Central Kenya were predominantly among children aged 12-23 months, both before and after the vaccine. Following vaccine introduction, a large proportion of adenovirus cases occurred among children aged 12-23 months in both regions. Norovirus peaked at 12-23 months in Central Kenya and showed dual peaks at 3-5 and 9-11 months in Western Kenya. Astrovirus infections in Western Kenya shifted from peaks at 6-8 and 24-59 months pre-vaccine to 9-11 months post-vaccine.
Conclusion: Our data demonstrate the burden and changing epidemiology of enteric viruses in Western and Central Kenya and underscores the need for continued monitoring to guide the design and implementation of appropriate public health interventions.
背景:轮状病毒、诺如病毒、腺病毒(40/41型)和星状病毒是全球幼儿急性胃肠炎最重要的病毒病原。肯尼亚于2014年7月将轮状病毒疫苗纳入其国家免疫规划,导致轮状病毒流行率显著下降。我们试图评估轮状病毒疫苗接种对肯尼亚不同地区其他腹泻相关肠道病毒流行病学趋势的影响。方法:在引入轮状病毒疫苗之前(2011-2013年)和之后(2019-2020年),我们使用常规和多重RT-PCR分析了716份来自肯尼亚西部Mbita副县转诊医院和肯尼亚中部Kiambu县转诊医院的5岁以下急性胃肠炎儿童的粪便样本中腺病毒、星状病毒和诺如病毒的检测结果为阴性。结果:接种轮状病毒疫苗后,诺如病毒和星状病毒在中央区的流行率无显著差异(诺如病毒5.4% vs 5.9%;星状病毒- 2%对2.4%)和肯尼亚西部(诺如病毒- 2%对3%;Astrovirus 3.3% vs 5.9%)。尽管肯尼亚西部的腺病毒患病率大幅上升(9%对12.4%),但肯尼亚中部的腺病毒患病率显著下降(17%对6%,p = 0.007)。在引入轮状病毒疫苗之前,大部分腺病毒病例发生在肯尼亚中部6-8个月和西部12-23个月,而诺如病毒流行率最高的是中部12-23个月和西部3-5个月。肯尼亚中部的星状病毒感染主要发生在接种疫苗前后12-23个月的儿童中。在接种疫苗后,这两个地区的很大一部分腺病毒病例发生在12-23个月的儿童中。诺如病毒在肯尼亚中部12-23个月时达到高峰,在肯尼亚西部3-5个月和9-11个月时出现双峰。肯尼亚西部的星状病毒感染从接种疫苗前6-8个月和24-59个月的高峰转移到接种疫苗后9-11个月。结论:我们的数据显示了肯尼亚西部和中部地区肠道病毒的负担和不断变化的流行病学,并强调需要继续监测,以指导设计和实施适当的公共卫生干预措施。